RESUMO
Purpose: Population-based and registry studies have shown that chronic hypoparathyroidism is accompanied by long-term complications. We aimed to evaluate the risk of incident comorbidity among patients with chronic postsurgical hypoparathyroidism in real-life clinical practice in Spain. Methods: We performed a multicenter, retrospective cohort study including patients with chronic postsurgical hypoparathyroidism lasting ≥3 years with at least a follow-up visit between January 1, 2022 and September 15, 2023 (group H). The prevalence and incidence of chronic complications including chronic kidney disease, nephrolithiasis/nephrocalcinosis, hypertension, dyslipidemia, diabetes, cardiovascular disease, central nervous system disease, mental health disorders, eye disorders, bone mineral density alterations, fracture and cancer were evaluated. Patient data were compared with a group of patients who did not develop hypoparathyroidism, matched by gender, age, and follow-up time after thyroidectomy (group NH). Results: We included 337 patients in group H (median [IQR] age, 45 [36-56] years; median time of follow-up, 8.9 [6.0-13.0] years; women, 84.3%) and 669 in group NH (median age, 47 [37-55] years; median time of follow-up, 8.0 [5.3-12.0] years; women, 84.9%). No significant differences were found in the prevalence of comorbidities at the time of thyroidectomy between both groups. In multivariable adjusted analysis, patients with chronic hypoparathyroidism had significantly higher risk of incident chronic kidney disease (OR, 3.45; 95% CI, 1.72-6.91; P<0.001), nephrolithiasis (OR, 3.34; 95% CI, 1.55-7.22; P=0.002), and cardiovascular disease (OR, 2.03; 95% CI, 1.14-3.60; P=0.016), compared with patients without hypoparathyroidism. On the contrary, the risk of fracture was decreased in patients with hypoparathyroidism (OR, 0.09; 95% CI, 0.01-0.70; P=0.021). Conclusion: This study demonstrates that, in the clinical practice of Spanish endocrinologists, a significant increase in the risk of chronic kidney disease, nephrolithiasis and cardiovascular disease, as well as a reduction in the risk of fractures is detected. These results are of interest for the development of new clinical guidelines and monitoring protocols for patients with hypoparathyroidism.
Assuntos
Doenças Cardiovasculares , Fraturas Ósseas , Hipoparatireoidismo , Nefrolitíase , Insuficiência Renal Crônica , Feminino , Humanos , Pessoa de Meia-Idade , Doenças Cardiovasculares/etiologia , Comorbidade , Fraturas Ósseas/etiologia , Hipoparatireoidismo/etiologia , Hipoparatireoidismo/complicações , Nefrolitíase/complicações , Insuficiência Renal Crônica/etiologia , Insuficiência Renal Crônica/complicações , Estudos Retrospectivos , Tireoidectomia/efeitos adversos , Masculino , AdultoRESUMO
OBJECTIVE: There is hardly any information on the consumption of healthcare resources by older people with differentiated thyroid cancer (DTC). We analyzed these consumptions in older patients with DTC and compared patients 75 years and older with subjects aged 60-74 years. METHODS: A multicenter, retrospective analysis was designed. We recorded three groups of health resources consumption (visits, diagnostic procedures, and therapeutic procedures) and identified a subgroup of patients with high consumption of resources. We compared patients aged between 60-74 years (group 1) with patients aged 75 and over (group 2). RESULTS: We included 1654 patients (women, 74.4%), of whom 1388 (83.9%) belonged to group 1 and 266 (16.1%) to group 2. In group 2, we found a higher proportion of patients requiring emergency department visits (7.9 vs. 4.3%, P = 0.019) and imaging studies (24.1 vs. 17.3%; P = 0.012) compared to group 1. However, we did not find any significant difference between both groups in the consumption of other visits, diagnostic procedures, or therapeutic procedures. Overall, 340 patients (20.6%) were identified as high consumers of health resources, 270 (19.5%) in group 1 and 70 (26.3%) in group 2 (P = 0.013). Multivariate logistic regression analysis showed that the risk of recurrence and mortality, radioiodine treatment, tumor size, and vascular invasion were significantly related to the high global consumption of resources. However, the age was not significantly related to it. CONCLUSION: In patients with DTC over 60 years of age, advanced age is not an independent determining factor in the consumption of health resources.
Assuntos
Adenocarcinoma , Neoplasias da Glândula Tireoide , Humanos , Feminino , Pessoa de Meia-Idade , Idoso , Estudos Retrospectivos , Radioisótopos do Iodo/uso terapêutico , Neoplasias da Glândula Tireoide/patologia , Adenocarcinoma/tratamento farmacológico , Tireoidectomia/métodosRESUMO
PURPOSE: We investigated whether age at diagnosis of differentiated thyroid carcinoma (DTC) may be a risk factor for structural disease and mortality after primary treatment in aging patients. METHODS: A multicenter, retrospective analysis including patients older than 60 years at DCT diagnosis was designed. All subjects were treated by surgery with or without radioiodine adjuvant therapy and had a minimum follow-up of one year. We compared elderly patients (group 1, 60-74 years) with very old patients (group 2, ≥75 years). RESULTS: The study involved 1668 patients (74.3% women, median age 67 years, 87.6% papillary thyroid cancer, 73.3% treated with radioiodine), including 1397 in group 1 and 271 in group 2. Patients in group 2 had larger tumor size (1.8 [0.8-3.0] vs 1.5 [0.7-2.8] cm; P = 0.005), higher proportions of tumors with vascular invasion (23.8 vs 16.4%; P = 0.006), and lower proportion of lymphocytic thyroiditis (18.6 vs 24.9%; P = 0.013) than subjects in group 1. Kaplan-Meier survival analysis showed that patients in group 2 had significantly lower structural disease-free survival (DFS) and overall survival (OS) than patients in group 1 (P = 0.035 and <0.001, respectively). In multivariate Cox regression analysis, age was a risk factor significantly associated with OS. However, age was significantly associated with DFS in unadjusted analysis and in analysis adjusted by gender and risk classification variables, but not when pathological and therapy-related variables were introduced in the model. On the other hand, patients who received radioiodine had worse DFS (P < 0.001) compared to those who did not. CONCLUSION: Although age is a conditioning factor for OS, very old patients do not have a greater risk of developing structural disease throughout the follow-up than elderly patients with DTC.
Assuntos
Radioisótopos do Iodo , Neoplasias da Glândula Tireoide , Idoso , Intervalo Livre de Doença , Feminino , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Prognóstico , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/patologia , TireoidectomiaRESUMO
INTRODUCTION: In many cases of drug allergy, it is necessary to do in vitro test, for several reasons. BAT (basophil activation test) is a very useful weapon in these cases. In many iv. or im. depot preparations, the culprit of the allergic reaction is an excipient, and not the main component. CASE REPORT: A 37-year-old male, suffering from a Klinefelter syndrome needed treatment with a preparation of undecanoate of testosterone (Reandron). With the last administered dose, he suffered an anaphylactic shock with Kounis syndrome. The patient declined any in vivo studies, so we thought of BAT as a possibility for the diagnosis. The results were remarkable, showing a very high positivity to castor oil. CONCLUSIONS: This is the second case in the world of anaphylaxis to a preparation of Testosterone, and the first one with the castor oil (also called Cremophor or Kolliphor) as responsible. El BAT was essential for the diagnosis and ulterior treatment of this patient. This is the first time, that this study with BAT, has been done with a Testosterone preparation.
Introducción: En muchos casos de alergia a medicamentos, es necesario realizar pruebas in vitro por diversos motivos. La PAB (prueba de activación de basófilos) es un arma útil en estos casos. Reporte de caso: Se trata de un hombre de 37 años en tratamiento con undecanoato de testosterona relacionado a síndrome de Klinefelter; que al momento de la última minsitración de la dosis, el paciente sufrió un choque anafiláctico acompañado de síndrome de Kounis. Por la necesidad de seguir con el tratamiento con testosterona, decidimos recurrir a la PAB para el diagnóstico, y los resultados fueron concluyentes, se documentó positividad al aceite de ricino. Conclusiones: A nivel mundial, este es el segundo caso de anafilaxia asociado a undecanoato de testosterona y el primero donde el aceite de ricino ha sido el responsable. La PAB se hizo necesaria para el diagnóstico y el posterior tratamiento de este paciente.
Assuntos
Anafilaxia , Hipersensibilidade a Drogas , Adulto , Anafilaxia/induzido quimicamente , Anafilaxia/diagnóstico , Anafilaxia/tratamento farmacológico , Basófilos , Humanos , Masculino , Testosterona/efeitos adversosRESUMO
OBJECTIVE: We aimed to study the predictive factors for recovery of parathyroid function in hypoparathyroid patients after total thyroidectomy for thyroid cancer. METHODS: We designed a retrospective, multicentre and nation-wide analysis of patients with total thyroidectomy who were seen in twenty endocrinology departments from January to March 2018. We selected patients with histologically proven thyroid cancer and retrieved information related to surgical procedure and thyroid cancer features. Survival analysis and Cox regression analysis were used to study the relationship between these variables and the recovery of parathyroid function. RESULTS: From 685 patients with hypoparathyroidism at discharge of surgery, 495 (72.3%) recovered parathyroid function over time. Kaplan-Meier analysis showed that this recovery was significantly related to the presence of specialized surgical team (P<0.001), identification of parathyroid glands at surgery (P<0.001), papillary histopathology (P=0.040), and higher levels of postoperative calcium (Ca) (P<0.001) and parathyroid hormone (PTH) (P<0.001). Subjects with gross extrathyroidal extension (P=0.040), lymph node metastases (P=0.004), and surgical re-intervention after initial surgery (P=0.024) exhibited a significant risk of persistence of hypoparathyroidism. Multivariate Cox regression analysis showed that the significant and independent factors for recovery of parathyroid function were postoperative concentrations of Ca (P=0.038) and PTH (P=0.049). The presence of lymph node metastases was a negative predictor of recuperation of parathyroid function (P=0.042) in this analysis. CONCLUSION: In patients with thyroid cancer, recovery of parathyroid function after total thyroidectomy was directly related to postoperative Ca and PTH concentrations, and inversely related to lymph node metastases.
Assuntos
Hipoparatireoidismo , Glândulas Paratireoides/fisiopatologia , Neoplasias da Glândula Tireoide , Tireoidectomia , Cálcio/sangue , Humanos , Hipoparatireoidismo/etiologia , Metástase Linfática , Hormônio Paratireóideo/sangue , Alta do Paciente , Complicações Pós-Operatórias , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia/efeitos adversosRESUMO
BACKGROUND: Recent guidelines for the treatment of hypoparathyroidism emphasize the need for long-term disease control, avoiding symptoms and hypocalcaemia. Our aim has been to analyze the prevalence of poor disease control in a national cohort of patients with hypoparathyroidism, as well as to evaluate predictive variables of inadequate disease control. METHODS: From a nation-wide observational study including a cohort of 1792 patients undergoing total thyroidectomy, we selected 260 subjects [207 women and 53 men, aged (mean ± SD) 47.2±14.8 years] diagnosed with permanent hypoparathyroidism. In every patient demographic data and details on surgical procedure, histopathology, calcium (Ca) metabolism, and therapy with Ca and calcitriol were retrospectively collected. A patient was considered not adequately controlled (NAC) if presented symptoms of hypocalcemia or biochemical data showing low serum Ca levels or high urinary Ca excretion. RESULTS: Two hundred and twenty-one (85.0%) patients were adequately controlled (AC) and 39 (15.0%) were NAC. Comparison between AC and NAC patients did not show any significant difference in demographic, surgical, and pathological features. Rate of hospitalization during follow-up was significantly higher among NAC patients in comparison with AC patients (35.9% vs. 10.9%, P<0.001). Dose of oral Ca and calcitriol were also significantly higher in NAC subjects. In a subgroup of 129 patients with serum parathyroid hormone (PTH) levels available, we found that NAC patients exhibited significantly lower postoperative PTH concentrations than AC patients [median (interquartile range) 3 (1.9-7.8) vs. 6.9 (3.0-11) pg/mL; P=0.009]. CONCLUSIONS: In a nation-wide cohort of 260 subjects with definitive hypoparathyroidism, 15% of them had poor disease control. These patients required higher doses of oral Ca and calcitriol, had higher rate of hospitalization during follow-up and showed lower PTH concentrations in the postoperative period.
RESUMO
Subclinical thyroid disease is a biochemical diagnosis and is common during pregnancy. Because of the physiological hormonal changes that take place during pregnancy and the absence of normal ranges for thyroid hormones during this period, subclinical thyroid disease is difficult to interpret during pregnancy. Subclinical hyperthyroidism during pregnancy has few clinical consequences and no treatment is required. In contrast, subclinical hypothyroidism seems to improve with thyroxine treatment. Iodine supplements during pregnancy and lactation, even in iodine-sufficient areas, are also indicated.
Assuntos
Hipertireoidismo/diagnóstico , Hipertireoidismo/tratamento farmacológico , Hipotireoidismo/diagnóstico , Hipotireoidismo/tratamento farmacológico , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/tratamento farmacológico , Adulto , Desenvolvimento Embrionário , Feminino , Doenças Fetais/etiologia , Doenças Fetais/prevenção & controle , Humanos , Hipertireoidismo/sangue , Hipotireoidismo/sangue , Iodo/administração & dosagem , Iodo/deficiência , Iodo/uso terapêutico , Lactação , Necessidades Nutricionais , Gravidez , Complicações na Gravidez/sangue , Transtornos Puerperais/tratamento farmacológico , Hormônios Tireóideos/sangue , Tireoidite Autoimune/sangue , Tireoidite Autoimune/diagnóstico , Tireoidite Autoimune/tratamento farmacológico , Tireotropina/sangue , Tiroxina/uso terapêuticoRESUMO
PURPOSE: The prevalence of postoperative hypoparathyroidism has been studied in registries and in surgical series with highly variable and imprecise results. However, the frequency of this hormonal deficiency in the clinical practice of endocrinologists is not known with accuracy. We aimed to assess the prevalence and risk factors of hypoparathyroidism in patients undergoing total thyroidectomy in Spain. METHODS: We designed a retrospective, multicentre and nation-wide protocol including all patients with total thyroidectomy who were seen in the endocrinology clinic of the participant centers from January to March 2018. Prevalence of hypoparathyroidism was evaluated at discharge of surgery, 3-6 months after surgery, 12 months after surgery and at last visit. Twenty hospitals participated in the study. RESULTS: Of 1792 patients undergoing total thyroidectomy, 866 (48.3%) developed postoperative hypoparathyroidism at discharge of surgery. Most of them recover parathyroid function over time. Prevalence of hypoparathyroidism at 3-6 months, 12 months and at last visit was 22.9%, 16.7% and 14.5%, respectively. The risk of developing definitive hypoparathyroidism was related to the presence of parathyroid tissue at histology, lymph node dissection, and two-stage thyroidectomy. Patients with thyroid cancer, with higher postoperative calcium levels and treated by expert surgical teams exhibited lower risk of developing permanent hypoparathyroidism. CONCLUSIONS: Although most patients with postsurgical hypoparathyroidism recover parathyroid function, the prevalence of permanent disease in clinical practice is non negligible (14.5%). Postoperative calcium, extent and timing of surgery, the presence of cancer, expert surgical team, and parathyroid tissue at histology are predictors of permanent hypoparathyroidism.
Assuntos
Hipoparatireoidismo/epidemiologia , Complicações Pós-Operatórias/epidemiologia , Tireoidectomia/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Hipoparatireoidismo/etiologia , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Prevalência , Estudos Retrospectivos , Fatores de Risco , Espanha/epidemiologia , Adulto JovemRESUMO
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
RESUMO
Giant prolactinomas are rare tumors characterized by their large size, compressive symptoms, and extremely high prolactin secretion. The aim of this study is to describe our experience with a series of 16 giant prolactinomas cases in terms of clinical presentation, therapeutic decisions, and final outcomes. Retrospective analysis of adult patients diagnosed with giant prolactinomas at the endocrine departments of three university tertiary hospitals. We included 16 patients (43.7 % women); mean age at diagnosis: 42.1 ± 21 years. The most frequent presentation was compressive symptoms. The delay in diagnosis was higher in women (median of 150 months vs. 12 in men; p = 0.09). The mean maximum tumor diameter at diagnosis was 56.9 ± 15.5 mm, and mean prolactin levels were 10,995.9 ± 12,157.8 ng/mL. Dopamine agonists were the first-line treatment in 11 patients (mean maximum dose: 3.9 ± 3.2 mg/week). Surgery was the initial treatment in five patients and the second-line treatment in six. Radiotherapy was used in four cases. All patients but one, are still with dopamine agonists. After a mean follow-up of 9 years, prolactin normalized in 7/16 patients (43.7 %) and 13 patients (81 %) reached prolactin levels lower than twice the upper limit of normal. Mean prolactin level at last visit: 79.5 ± 143 ng/mL. Tumor volume was decreased by 93.8 ± 11.3 %, and final maximum tumor diameter was 18.4 ± 18.8 mm. Three patients are actually tumor free. Giant prolactinomas are characterized by a large tumor volume and extreme prolactin hypersecretion. Multimodal treatment is frequently required to obtain biochemical and tumor control.
Assuntos
Agonistas de Dopamina/uso terapêutico , Procedimentos Neurocirúrgicos/métodos , Hipófise/cirurgia , Neoplasias Hipofisárias/terapia , Prolactinoma/terapia , Radioterapia , Adulto , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Hipofisárias/sangue , Prolactina/sangue , Prolactinoma/sangue , Resultado do Tratamento , Adulto JovemAssuntos
Antineoplásicos/uso terapêutico , Carcinoma/tratamento farmacológico , Terapias em Estudo/tendências , Neoplasias da Glândula Tireoide/tratamento farmacológico , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos Hormonais/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma/genética , Carcinoma/secundário , Ensaios Clínicos como Assunto , Humanos , Terapia de Alvo Molecular , Estudos Multicêntricos como Assunto , Proteínas de Neoplasias/antagonistas & inibidores , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/imunologia , Guias de Prática Clínica como Assunto , Inibidores de Proteínas Quinases/uso terapêutico , Neoplasias da Glândula Tireoide/genética , Neoplasias da Glândula Tireoide/patologia , Resultado do TratamentoRESUMO
La disfunción tiroidea subclínica es de diagnóstico bioquímico y es una entidad frecuente durante la gestación. Los cambios hormonales fisiológicos que acontecen durante la gestación, junto con la falta de valores de referencia de las hormonas tiroideas en este periodo, hacen que la disfunción tiroidea subclínica sea de difícil interpretación. Mientras el hipertiroidismo subclínico en la gestación carece de repercusión clínica y no requiere una actuación específica, el hipotiroidismo subclínico, en ese periodo, parece beneficiarse del tratamiento sustitutivo con tiroxina. Los suplementos de yodo en la gestación y lactación son necesarios incluso en zonas de yodosuficiencia (AU)
Subclinical thyroid disease is a biochemical diagnosis and is common during pregnancy. Because of the physiological hormonal changes that take place during pregnancy and the absence of normal ranges for thyroid hormones during this period, subclinical thyroid disease is difficult to interpret during pregnancy. Subclinical hyperthyroidism during pregnancy has few clinical consequences and no treatment is required. In contrast, subclinical hypothyroidism seems to improve with thyroxine treatment. Iodine supplements during pregnancy and lactation, even in iodine-sufficient areas, are also indicated (AU)
Assuntos
Humanos , Feminino , Gravidez , Adulto , Hipertireoidismo/diagnóstico , Hipotireoidismo/diagnóstico , Complicações na Gravidez/diagnóstico , Hipertireoidismo/tratamento farmacológico , Hipotireoidismo/tratamento farmacológico , Iodo/uso terapêutico , Suplementos Nutricionais , Tiroxina/uso terapêutico , Hormônios TireóideosRESUMO
La disminución brusca de concentraciones plasmáticas de corticoides puede producir un auténtico síndrome de abstinencia similar al que se produce con cualquier droga. Presentamos el caso de una mujer con síndrome de abstinencia tras el tratamiento quirúrgico de un síndrome de Cushing, que no fue identificado, por lo que se mantuvo de forma innecesaria el tratamiento con glucocorticoides (AU)
Sharp reductions in plasma corticosteroid levels can produce a genuine withdrawal syndrome similar to that induced by withdrawal of any other drug. We describe the case of a woman who, after undergoing surgical treatment for Cushing's syndrome, suffered from a withdrawal syndrome. Because this syndrome was not identified, the patient was unnecessarily maintained on glucocorticoid treatment (AU)
Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Corticosteroides/deficiência , Síndrome de Cushing/tratamento farmacológico , Glucocorticoides/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias , Testes de Função TireóideaRESUMO
En la práctica clínica son frecuentes los pacientes con disfunción tiroidea subclínica. Es decir, pacientes con concentraciones de tirotropina (TSH) fuera de los valores de referencia pero con concentraciones de tiroxina libre y triyodotironina libre normales. En el presente artículo, se describe qué es la disfunción tiroidea subclínica, se revisa su epidemiología, se recomienda el abordaje más apropiado, se evalúan los riesgos y beneficios del tratamiento y se establece la utilidad de su cribado en ciertos grupos de población. En definitiva, son limitadas las evidencias que sugieren una asociación de la disfunción tiroidea subclínica con ciertos síntomas o con el beneficio o riesgos de su tratamiento. Las consecuencias de la disfunción tiroidea subclínica (TSH: 0,1-0,45 mU/l o 4,5-10 mU/l) son escasas y no se puede recomendar el tratamiento rutinario de estos pacientes. Asimismo, no se puede recomendar el cribado indiscriminado de la población. No obstante, se debe buscar con insistencia en mujeres embarazadas de riesgo, mujeres mayores de 60 años y en ciertos grupos de riesgo (AU)
Patients with serum thyroid-stimulating hormone (TSH) outside the reference range and levels of free thyroxine and free triiodothyronine within the reference range are common in clinical practice. In the present article, subclinical thyroid disease is defined and its epidemiology reviewed. Recommendations on appropriate evaluation and the risks and benefits of treatment and consequences of non-treatment are explored. The question of whether population-based screening is warranted is also discussed. Data supporting an association between subclinical thyroid disease and symptoms or adverse clinical outcomes or benefits of treatment are scarce. The consequences of subclinical thyroid disease (serum TSH 0.1-0.45 mU/l or 4.5-10.0 mU/l) are minimal and recommendations against routine treatment of patients with TSH levels in these ranges are provided. There is insufficient evidence to support population-based screening. Nevertheless, pertinacious case finding is appropriate in pregnant women at risk, women older than 60 years, and others at high risk for thyroid dysfunction (AU)